Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Clinical evidence

Integrated externally controlled survival analysis

56 evidence topics · 12 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using overall survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Company-presented survival analysis with broader external controls: prespecified subgroup analyses
Company-presented survival analysis with broader external controls: sensitivity analyses
Results
Participant disposition
Baseline characteristics
Company-presented survival analysis with broader external controls: baseline characteristics of 72 treated and 119 matched controls
CharacteristicAdrabetadex (N=72)External control (N=119)
Age at onset under 2 years, n/N (%)“32/72 (44)”“57/119 (48)”
Age at onset 2 to under 6 years, n/N (%)“40/72 (56)”“62/119 (52)”
Median age at neurological onset, months (Q1, Q3)“25 (0, 68)”“24 (0, 68)”
Overall miglustat use, n/N (%)“52/72 (72)”“72/119 (61)”
Gastrostomy tube, n/N (%)“11/50 (22)”“6/26 (23)”
Respiratory therapy, n/N (%)“9/50 (18)”“2/26 (8)”
Race White, n/N (%)“65/72 (90)”“22/26 (85)”
Race other, n/N (%)“7/72 (10)”“4/26 (15)”
Region Europe, n/N (%)“11/72 (15)”“90/119 (76)”
Region North America, n/N (%)“61/72 (85)”“27/119 (23)”
Region South America, n/N (%)“0 (0)”“2/119 (2)”
Efficacy results
Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026
Population and comparator sourceDeaths, treated (%)Deaths, control (%)Hazard ratio (95% CI)P-value
Overall infantile, pooled comparator“9 (13.6%)”“42 (63.3%)”“0.162 (0.069, 0.380)”“<0.0001”
Early infantile, pooled comparator“6 (18.8%)”“23 (72.8%)”“0.109 (0.035, 0.333)”“<0.0001”
Late infantile, pooled comparator“3 (8.8%)”“18 (54.3%)”“0.148 (0.040, 0.546)”“0.0036”
With miglustat“2 (7.1%)”“12 (41.8%)”“0.097 (0.023, 0.406)”“0.0005”
Without miglustat“5 (21.7%)”“18 (79.9%)”“0.123 (0.036, 0.425)”“<0.0001”
French comparator“5 (9.8%)”“42 (82.1%)”“0.073 (0.023, 0.236)”“<0.0001”
NIH comparator“5 (15.2%)”“24 (71.2%)”“0.176 (0.060, 0.517)”“<0.0001”
YODA comparator“4 (11.4%)”“6 (17.9%)”“0.298 (0.082, 1.086)”“0.1168”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations of the integrated externally controlled survival analysis
  • Design: the comparison is with external controls. A statistical methods poster on the analysis states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies, and that target trial emulation identified four principal threats: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias. Both the label analysis and the company analysis required each matched control to be alive at the treated participant's age at treatment initiation.
  • Label analysis: all 26 external control participants came from Study 1 and were weighted to a number of 36 against 36 treated participants. Matching used disease subtype, age of neurological symptom onset (±3 months), and baseline miglustat use; 58% of treated and 33% of control participants were male, median follow-up from the index age was 5.6 and 4.2 years, and index ages ranged from 1 to 19 years. The label states that safety and effectiveness in reducing mortality with neurological onset at 6 years of age or older has not been established.
  • Analysis with broader external controls: 72 treated participants were matched with 119 external controls drawn from 4 major disease databases or publications, and the poster states that comparability factors were not available from all sources.
  • Variation in the estimate: the hazard ratio differed by comparator source (French 0.113; NIH 0.449, 95% CI 0.214 to 0.946; YODA 0.381, 95% CI 0.128 to 1.137, P = 0.1426) and between data cuts (0.162 with 66 treated participants at the June 24, 2024 cutoff; 0.289 with 72 at the January 10, 2025 cutoff). The label analysis reported 0.45 (0.21, 0.95). The statistical methods poster reported that hazard ratio estimates across its prespecified sensitivity analyses remained consistent with the primary analysis.
  • Analysis plan: the YODA Project data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory” and that no minimum sample size was determined a priori.